Stocktoria
MapLight Therapeutics, Inc. MPLT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2025-10-27
MapLight Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 |
|---|---|---|
| R&D expense | $138.3M | $68.5M |
| Operating income | -$169.1M | -$82.9M |
| Net income | -$161.2M | -$77.6M |
| EPS (diluted) | $-18.56 | $-105.38 |
| Operating cash flow | -$138.1M | -$78.8M |
| Free cash flow | -$138.6M | -$79.6M |
| Cash & equivalents | $46.7M | $38.3M |
| Total assets | $479.5M | $136.9M |
| Total liabilities | $21.1M | $21.7M |
| Shareholders' equity | $458.4M | -$193.6M |
Source: SEC EDGAR filings · CIK 0001770069 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.